Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hypercholesterolemia (LDL-C ≥ 100 mg/dL)~* At high risk of CHD~* On stable, maximally tolerated statin therapy for 8 weeks~* On stable, low fat diet for 12 weeks~* Stable weight for 6 weeks~Exclusion Criteria:~* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, liver disease, cancer, type I diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once a week for 26 weeks.
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).